Venture capital deployment into 3D pharmaceutical printing has reached $2.3 billion in the first half of 2026, with Series C rounds dominating as early-stage technologies transition to commercial scale. The investment thesis has shifted from hardware innovation toward software platforms that integrate prescription data, pharmacogenomic profiles, and manufacturing parameters. US...